(Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced in addition to developing TH104 for the proposed ...
LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and ...
Long-term nemolizumab use reduces itch, disease severity, and steroid dependence in patients with prurigo nodularis in a ...
EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...
Health officials in Fort Bend County have confirmed the first case of measles in the area. The patient is a woman in her 50s, who recently traveled ...
Mirum Pharmaceuticals (MIRM) announced that its partner, Takeda (TAK), has received approval by the Japanese Ministry of Health, Labour, and ...
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...
Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...
Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...
Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback